參考文獻(xiàn)/References:
[1] 郎景和,冷金花,周應(yīng)芳,等. 子宮內(nèi)膜異位癥[J]. 現(xiàn)代婦產(chǎn)科進(jìn)展,2006,15(3):161-172
[2] Rashidi B H,Sarhangi N,Aminimoghaddam S,et al. Association of vascular endothelial growth factor (VEGF)Gene polymorphisms and expression with the risk of endometriosis:a case control study[J]. Mol Biol Rep,2019,46(3):3445-3450
[3] Mohamed M L,El Behery M M,Mansour S A. Comparative study between VEGF A and CA 125 in diagnosis and follow up of advanced endometriosis after conservative laparoscopic surgery[J]. Arch Gynecol Obstet,2013,287(1):77-82
[4] Zheng P,Mei J,Leng J,et al. Evaluation of the brain functional activities in rats various location endometriosis pain model[J]. Ann Transl Med,2019,7(23):767.
[5] 愛虛老人. 《古方匯精》[M]. 北京:中國(guó)中醫(yī)藥出版社,2016:118-191.
[6] 郎景和. 子宮內(nèi)膜異位癥的基礎(chǔ)與臨床研究(第1卷)[M]. 北京:中國(guó)協(xié)和醫(yī)科大學(xué)出版社,2003:11-13
[7] Vigano P,D apres la communication de. Perspectives on endometriosis:new physio pathologic approaches and treatments[J]. J Gynecol Obstet Biol Reprod(Pairs),2003,32(8):S28-S31
[8] 唐宗海. 《血證論》[M]. 北京:人民衛(wèi)生出版社,2005:33-35.
[9] Liang R,Zhao Q,Jian G,et al. Tanshinone IIA Attenuates Contrast Induced Nephropathy via Nrf2 Activation in Rats[J]. Cell Physiol Biochem,2018,46(6):2616-2623
[10] 張璇,王小紅,林妍,等. 逐瘀湯對(duì)血瘀型子宮內(nèi)膜異位癥性不孕的療效觀察[J]. 福建醫(yī)藥雜志,2017,39(5):101-103
[11] 陳捷,張璇,陳麗笙,等. 腹腔鏡配合自擬逐瘀湯治療血瘀型子宮內(nèi)膜異位癥的臨床觀察[J]. 成都中醫(yī)藥大學(xué)學(xué)報(bào),2010,33(2):29-31
[12] 張璇,莊良武,陳蓉艷,等. 逐瘀湯對(duì)子宮內(nèi)膜異位癥大鼠白介素6、白介素8、腫瘤壞死因子α的影響[J]. 成都中醫(yī)藥大學(xué)學(xué)報(bào),2021,44(2):49-52
[13] 中國(guó)醫(yī)師協(xié)會(huì)婦產(chǎn)科醫(yī)師分會(huì)子宮內(nèi)膜異位癥專業(yè)委員會(huì) 中華醫(yī)學(xué)會(huì)婦產(chǎn)科學(xué)分會(huì)子宮內(nèi)膜異位癥協(xié)作組. 子宮內(nèi)膜異位癥長(zhǎng)期管理中國(guó)專家共識(shí)2018[J]. 中華婦產(chǎn)科雜志,2018,53(12):836-838.